Pfizer Inc. (PFE)
Pre-market:
| Previous close | 27.70 |
| Open | 27.86 |
| Bid | 27.90 x 2900 |
| Ask | 27.90 x 2200 |
| Day's range | 27.52 - 27.91 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 41,164,450 |
| Market cap | 157.475B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.68 (6.04%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Business Wire
Pfizer Announces New Chief Strategy and Innovation Officer
NEW YORK, May 06, 2024--Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins Pfizer from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morg
- Business Wire
Pfizer Reports First-Quarter 2024 Results
NEW YORK, May 01, 2024--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6).
- Business Wire
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
